Fabomotizole (trade name: Afobazole) is an anxiolytic peptide developed in the early 2000s by the Russian Academy of Medical Sciences. The goal of the researchers at the time was to create a selective anxiolytic agent that would not have the adverse effects of benzodiazepines.
Scientific studies concluded that Afobazole has an efficacy equivalent to that of Diazepam for the treatment of generalized anxiety disorder (GAD) and also demonstrated that Afobazole can reduce microglial toxicity and cell death following prolonged ischemic exposure as well as decrease ischemia-induced neuronal cell death.
Fabomotizole is used in Russia to treat the following symptoms:
Afobazole, 60 capsules (10mg)
This product has not been evaluated by the FDA and is not intended to diagnose, cure, or prevent any disease.
Safety Information: Keep this product out of the reach of children. This product is not a dietary supplement. It is a research compound, sold as a raw material. It may result in adverse effects if improperly handled or consumed. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material.
Cymnootropics.com can’t be held responsible for any adverse effects that may arise from improper handling and/or consumption of this product.
Subscribe and receive news about our special sales and coupons